Biopharmaceutical company Verdiva Bio has completed its participant enrolment for the Phase IIb study of its once-weekly oral GLP-1. 

VRB-101 is a once-weekly oral, cAMP-biased, GLP-1 peptide analogue candidate for body weight reduction in people with overweight or obesity. 

The Phase IIb EVOLVE-2 trial is randomised, double-blind and placebo-controlled, evaluating the safety, tolerability and efficacy of VRB-101 for body weight reduction. The study enrolled over 200 participants who have obesity or are overweight with at least one weight-related comorbidity across 22 sites in the US. 

“Obesity is a multifactorial chronic disease with important health-related complications requiring long-term therapy,” stated Dr Mohamed Eid, CMO at Verdiva Bio. 

“Previous studies indicate a promising clinical profile for VRB-101, supported by PK modelling which suggest VRB-101’s ability to achieve drug levels similar to or higher than a once-weekly injectable GLP-1 peptide currently approved in the US and other major markets. 

“VRB-101 appears to have the potential to become a first-in-class once-weekly oral GLP-1 analogue for people living with obesity or overweight and weight-related complications.” 

Topline results from the trial are expected by the end of 2026.